Compare Abeona Therapeutics Inc (ABEO) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KE Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while KE Holdings Inc trades at $15.33 (market cap $16.40B). The key difference: KE Holdings Inc is far larger — about 43.9× Abeona Therapeutics Inc's market cap, and KE Holdings Inc pays a 1.86% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BEKE | |
|---|---|---|
Market Cap | $373.32M | $16.40B |
Sector | Health | Technology |
52-Week High | $7.23 | $20.36 |
52-Week Low | $4.17 | $14.26 |
Enterprise Value | $228.22M | $12.17B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BEKE trades at $15.02, down 0.46% with a bearish technical signal. The company reported strong Q1 2026 earnings beating expectations with EPS of $0.20 versus $0.14 expected, driven by improved profitability despite lower revenue. Analyst sentiment remains overwhelmingly positive with 91.7% buy ratings. Recent news highlights potential trend reversal opportunities after a 14.1% decline over four weeks.
The outlook suggests potential upside with improving operational efficiency and cost controls offsetting market softness. Key risks include China's property market volatility and competitive pressures. With strong institutional support and positive earnings momentum, BEKE presents a compelling growth story despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
